May 15, 2019 / 09:20PM GMT
Michael Leonidovich Ryskin - BofA Merrill Lynch, Research Division - Associate
To kick off our next session, we're joined by Bio-Techne. I'm Mike Ryskin on the life science tools and diagnostics team here on behalf of Derek Brown. I think we're going to start with a quick intro presentation then we'll do a little bit of fireside chat but also we can open up to the audience for questions so...
James T. Hippel - Bio-Techne Corporation - Senior VP of Finance & CFO
Great. So I'm Jim Hippel, the CFO of Bio-Techne. I see some familiar faces in here but I also see some unfamiliar ones. So I'm not going to spend a ton of time describing the company, but I will spend just a few minutes here to get everyone on the same page.
Bio-Techne is essentially a 40-year-old-plus company that is a life science tools reagent provider and a world leader manufacturer of proteins, antibodies, assay kits and controls for diagnostic instruments. Roughly 5 or 6 years ago, a new CEO, Chuck Kummeth, came in and basically [continues] -- worked on a strategy with the company to
Bio-Techne Corp at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers